RCT: Ravidasvir plus sofosbuvir are effective and well tolerated in patients with chronic HCV infection, with potential as an affordable treatment for these patients
18 Apr, 2021 | 21:19h | UTC
Commentary on Twitter
Trial results of new affordable #hepatitisC treatment showing 97% cure rate now published in @LancetGastroHep!
Ravidasvir + sofosbuvir has the potential to provide an additional affordable, simple, and efficacious #publichealth tool to eliminate HCV.
➡️https://t.co/Oo1ZHQnyn6 pic.twitter.com/FcFntfYMSC
— Drugs for Neglected Diseases initiative (@DNDi) April 16, 2021